Alicia joined Paratus in January 2026 and brings more than 30 years of biotechnology leadership experience, with a strong track record in company building, product development, commercialization, fundraising and strategic transactions across both rare and prevalent diseases.
She most recently served as President and Chief Executive Officer of Atalanta Therapeutics, Inc., a privately held biotechnology company. Prior to Atalanta, Ms. Secor served as President and Chief Executive Officer of Juniper Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from August 2016 until August 2018, when the company was acquired by Catalent, Inc.
Alicia held several leadership positions including chief commercial officer at Zafgen Inc., chief operating officer at Synageva BioPharma Corp, and roles of increasing responsibility at Genzyme over her 15-year tenure, including serving as vice president and general manager of metabolic diseases. Prior to Genzyme, Alicia held positions at Alkermes, Inc. in business development, at Centocor, Inc. (a Johnson & Johnson Company) in clinical and commercial operations, and began her career at Pfizer Inc. as a hospital-based sales representative.
Alicia has significant board experience across the biotechnology sector, including currently serving as a director for Zevra Therapeutics, and former service on the boards of multiple public companies that were successfully acquired, including Orchard Therapeutics, G1 Therapeutics and GW Pharmaceuticals. She served for five years on the board of the non-profit Foundation for Prader-Willi Research and is a mentor at the Termeer Institute.
Alicia holds a B.S. in health administration from the University of New Hampshire, and an MBA from Northeastern University’s D’Amore-McKim School of Business.
